<DOC>
	<DOCNO>NCT01390077</DOCNO>
	<brief_summary>Nitisinone potent inhibitor enzyme catalyze formation homogentisic acid , even logical treatment alkaptonuria tyrosinemia , approve FDA.The objective research explore report age related difference toxicity nitisinone pharmacokinetic underpinnings develop optimal therapeutic requirement target population presymptomatic patient . The additional effect mixture amino acid exclude tyrosine explore take advantage protein synthesis avoid elevation tyrosine would otherwise limit optimal dosage nitisinone . The study design treat patient find optimal dosage nitisinone obtain maximal reduction level homogentisic acid maintain safe level tyrosine . The long term objective target population pre-symptomatic patient prevention characteristic effect joint cartilage tendon .</brief_summary>
	<brief_title>Nitisinone ( NTBC ) In Different Age Groups Of Patients With Alkaptonuria</brief_title>
	<detailed_description>Study procedure design : 1 . Develop method nitisinone measurement via tandem mass spectrometry ( MS/MS ) . 2 . Determine whether difference adult child could erase employ dosage regimen base m2 body surface area oppose per kg body weight , find recent study dichloroacetate 3 . Determine optimal dosage reduction urinary level homogentisic acid minimal elevation plasma level tyrosine target population pre-symptomatic patient . 4 . Determine optimal dos Tyrex prevent hypertyrosinemia allow maximal reduction homogentisic acid . Baseline study include ophthalmologic examination , echocardiogram , X-rays joint , MRI select joint financially plausible ; history physical examination emphasis joint tendon . Ideally MRI repeat 12 month interval thereafter . Ophthalmologic exam , x-rays kidney prostate , echocardiogram repeat approximately every 12 month , depend age subject nitisinone dose . Patients see every 3 month first year , 6 month interval month 36 . The timing visit may alter response modification nitisinone and/or Tyrex dos . Complete near complete elimination homogentisic acid excretion seek . Optimal NTBC dosage would judge yield plasma concentration tyrosine less 1000 mmol/L concomitant use tyrosine free amino acid supplement . Dosage escalate reduced dependent evidence accumulation nitisinone urinary level HGA . The maximum initial dose nitisinone adult adolescent patient 0.2/mg/kg/day , young patient may require large dose ; standard dose hypertyrosinemia 1mg/kg/day , tentatively use maximum dose population . Patients ask collect first morning 12 hour urine collection homogentisic acid p-hydroxyphenyllactic acid monitor level tyrosine . Accumulation test repeated study 3 month treatment . Trough level nitisinone collect prior 5-7 day dose increase and/or month 6 , 12 , 18 , 24 every 12 month . The SF-36 Health Status Survey , two page quality life questionnaire ask ADLs emotional/social impact disease , complete patient patient 's parent baseline every six month . At point study plasma tyrosine level great 900umol/L amount Tyrex dietary protein intake may modify , nitisinone dose may decrease . Protein Saver blood spot card , do patient 's home mail lab , give patient instruction blood collection check tyrosine level 5-7 day drug/dietary modification . These steps—the dietary modification diet record need , addition adjustment Tyrex , adjustment nitisinone dose , repeat tyrosine analysis—will repeat necessary .</detailed_description>
	<mesh_term>Alkaptonuria</mesh_term>
	<mesh_term>Ochronosis</mesh_term>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>1 . Diagnosis alkaptonuria document increased excretion homogentisic acid 2 . Willing able provide write , sign informed consent , age appropriate write assent write informed consent legally authorize representative study explain , prior researchrelated procedure . 3 . Willing able see UCSD Clinical Center Research satellite site study visit 4 . Possession insurance coverage standard care procedure , clearly state consent form 1 . Baseline tyrosine level 250 mmol/mL 2 . Baseline serum creatinine , creatine kinase , transaminases 2x upper limit normal 3 . Baseline anemia thrombocytopenia 4 . Current participation another investigational medication trial . 5 . Pregnant lactate woman 6 . Current keratopathy , contact use uncontrolled glaucoma 7 . History myocardial infarction arrhythmia 8 . History pulmonary insufficiency 9 . Psychiatric illness may interfere compliance communication 10 . Current malignancy hypertension</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>homogentisic acid</keyword>
</DOC>